Sino Biopharmaceutical Ltd represents values of innovation, integrity, and excellence in the biopharmaceutical industry. With a commitment to improving global health, the company focuses on research, development, and commercialization of high-quality, affordable medicines. Sino Biopharmaceutical Ltd's corporate philosophy revolves around patient-centric approaches, ensuring access to innovative therapies. By leveraging their robust R&D capabilities, extensive manufacturing network, and strategic partnerships, the company aims to contribute to the well-being of patients worldwide. With a strong emphasis on ethical conduct, Sino Biopharmaceutical Ltd strives to deliver sustainable growth and create value for its stakeholders.

Sino Biopharmaceutical Ltd is primarily present in China, Hong Kong, and Macau.

Sino Biopharmaceutical Ltd, a leading pharmaceutical company, has accomplished several significant milestones in its journey. With a strong focus on innovation and research, the company has made remarkable strides in the biopharmaceutical sector. Sino Biopharmaceutical Ltd achieved the successful development and commercialization of various high-quality drugs, targeting critical therapeutic areas such as oncology, cardiovascular diseases, and infectious diseases. Additionally, the company expanded its presence globally, establishing partnerships and collaborations with renowned institutions and key players in the industry. Sino Biopharmaceutical Ltd's commitment to delivering cutting-edge healthcare solutions has garnered recognition, positioning them as a trusted and reliable leader in the pharmaceutical market.

Sino Biopharmaceutical Ltd, founded in 2000, is a well-established pharmaceutical company based in China. With a strong focus on research, development, and production of innovative drugs, Sino Biopharmaceutical has gained recognition in the global healthcare industry. Over the years, the company has emerged as a major player in the Chinese pharmaceutical market, with a diverse portfolio of products ranging from prescription drugs to over-the-counter medications. Sino Biopharmaceutical is dedicated to enhancing people's quality of life by providing high-quality and affordable healthcare solutions. Through continuous innovation and strategic partnerships, the company has achieved significant growth, making it a promising investment opportunity in the pharmaceutical sector.

The main competitors of Sino Biopharmaceutical Ltd in the market include other prominent pharmaceutical companies such as Jiangsu Hengrui Medicine Co., Ltd., CSPC Pharmaceutical Group Limited, Hutchison China MediTech Limited, and Beijing SL Pharmaceutical Co., Ltd. These companies are renowned for their significant presence in the pharmaceutical industry and pose strong competition to Sino Biopharmaceutical Ltd.

Sino Biopharmaceutical Ltd is primarily active in the pharmaceutical industry.

Sino Biopharmaceutical Ltd operates in the biopharmaceutical industry, specializing in the research, development, manufacturing, and distribution of pharmaceutical products. Their business model focuses on producing high-quality generic drugs, innovative biologics, and chemical drugs. Sino Biopharmaceutical aims to provide affordable and accessible healthcare solutions to patients globally. Through strategic partnerships and acquisitions, the company continuously expands its product portfolio and customer base. Sino Biopharmaceutical's dedication to technological advancements and R&D efforts strengthens its competitive advantage in the market, positioning them as a leading player in the biopharmaceutical sector.

Sino Biopharmaceutical KGV ir 19,42.

Sino Biopharmaceutical KUV ir 1,78.

AlleAktien kvalitātes vērtējums Sino Biopharmaceutical ir 7/10.

gaidāmā Sino Biopharmaceutical apgrozījums ir 29,51 miljardi CNY.

gaidāmā Sino Biopharmaceutical peļņa ir 2,70 miljardi CNY.

Sino Biopharmaceutical Ltd. is a pharmaceutical company based in Hong Kong that focuses on the research, development, manufacturing, and sales of pharmaceutical products. The company offers a wide range of products and services for people suffering from various diseases and health conditions. The business model of Sino Biopharmaceutical Ltd. is based on various business sectors, all of which are aimed at providing high-quality and innovative pharmaceutical products. These sectors include research and development, production and distribution of medicines, marketing and sales, biotechnology, and investment activities. The research and development department of Sino Biopharmaceutical Ltd. strives to promote innovation in drug development. The company invests heavily in the exploration of new drugs to treat diseases, including cancer, diabetes, cardiovascular diseases, and gastroenterology. The company has a strong research and development pipeline with numerous clinical trials for different drugs. The production of drugs is another important business sector of Sino Biopharmaceutical Ltd. The company has a wide range of drug production facilities, including solid dosage forms, liquid forms, and semi-solid forms. These facilities operate according to the highest international standards to ensure that the products are safe, effective, and of the highest quality. The company has a strong presence in China and also operates in the international market. It has launched a wide range of products for the treatment of various diseases. Some of the company's key products include tumor therapeutics, cardiovascular drugs, anti-infectives, digestive promoters, and the bleeding drug etamsylate. The company also has a strong marketing and sales department that is able to position and promote its products in the market. It uses a variety of distribution channels, including retail pharmacies, hospitals, physician networks, and online platforms, to sell its products. The company also has a separate biotechnology department that focuses on researching new technologies to advance medical research. It also has extensive activity in biotechnology investments. The company heavily invests in new startups and companies specializing in the development of biotechnology products. Overall, Sino Biopharmaceutical Ltd. has built a successful business model focused on providing high-quality and innovative medicines. The company has a strong presence in China and the international market, and its products are used by a wide range of customers to treat various diseases and conditions.

Sino Biopharmaceutical izmaksā dividendes 0,10 CNY, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Sino Biopharmaceutical vai uzņēmums nedod dividendes.

Sino Biopharmaceutical ISIN ir KYG8167W1380.

Sino Biopharmaceutical WKN ir A0CBDJ.

Sino Biopharmaceutical simbols ir 1177.HK.

Pēdējo 12 mēnešu laikā Sino Biopharmaceutical maksāja dividendes 0,08 CNY apmērā. Tas atbilst aptuveni 2,83 % dividendes ražībai. Nākamajos 12 mēnešos Sino Biopharmaceutical plāno maksāt dividendes 0,08 CNY apmērā.

Sino Biopharmaceutical pašreizējā dividendu rentabilitāte ir 2,83 %.

Sino Biopharmaceutical maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos oktobris, jūlijs, novembris, jūlijs.

Sino Biopharmaceutical pēdējo 26 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0,08 CNY. Tas atbilst dividendes ražībai 2,94 %.

Sino Biopharmaceutical tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Sino Biopharmaceutical apmērā 0,03 CNY, kas tika izmaksāta 5.07.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 11.06.2024..

Pēdējās dividendes izmaksa notika 5.07.2024..

Gadā 2023, Sino Biopharmaceutical izmaksāja 0,1 CNY dividendes.

Sino Biopharmaceutical dividendes tiek izmaksātas CNY.